Inhibitory rTMS in Dystonic Wilson Patients

checkorphan
Learn more about:
Wilson disease
Related Clinical Trial
Clinical Study of UX701 AAV-Mediated Gene Transfer for the Treatment of Wilson Disease Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840 A Phase I/II Study of VTX-801 in Adult Patients With Wilson’s Disease Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants. Clinical Evaluation and Assessment of Instruments and Biomarkers in Subjects With Wilson Disease Copper Concentration and Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840 Study of Retinal Vascular Parameters in Patients With Wilson’s Disease Evaluation of Patients With Liver Disease ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders The Assessment of Copper Parameters in Wilson Disease Subjects on Standard of Care Treatment Establishment of Human Cellular Disease Models for Wilson Disease Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson’s Disease in Japan. Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine A Controlled Study of Potential Therapeutic Effect of Oral Zinc in Manifesting Carriers of Wilson Disease Plasma Exchange and Continuous Hemodiafiltration in Treatment of Wilson’s Disease-related Liver Failure The Individual Therapy for Patients With Wilson’s Disease Study of Zinc for Wilson Disease Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson’s Disease Study of Tetrathiomolybdate in Patients With Wilson Disease Efficacy and Safety of ALXN1840 (Formerly Named WTX101) Administered for 48 Weeks Versus Standard of Care in Patients With Wilson Disease With an Extension Period of up to 60 Months WILSTIM – DBS (WILson STIMulation – Deep Brain Stimulation) Efficacy and Safety Study of Zinc Acetate to Treat Wilson’s Disease in Japan. Efficacy of Invitro Expanded Bone Marrow Derived Allogeneic Mesenchymal Stem Cell Transplantation Via Portal Vein or Hepatic Artery or Peripheral Vein in Patients With Wilson Cirrhosis Inhibitory rTMS in Dystonic Wilson Patients Natural History of Wilson Disease A Registered Cohort Study on Wilson’s Disease sCD163 and sMR in Wilsons Disease – Associations With Disease Severity and Fibrosis Cohort Research on Wilson’s Disease Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease A Phase 1 Study to Assess the Effects in the Body of a Single Dose of Trientine Dihydrochloride in Wilson’s Disease Patients Efficacy and Safety Study of WTX101 in Adult Wilson Disease Patients

Brief Title

Inhibitory rTMS in Dystonic Wilson Patients

Official Title

Study of Writing Improvement in Patients With Wilson Disease and Dystonia After One Session of Inhibitory Repetitive Transcranial Magnetic Stimulation

Brief Summary

      Wilson disease is a genetic disorder resulting in copper accumulation in liver, brain and
      eye. The neurologic complications include dystonic syndrome, which is a prolonged and
      excessive muscle activation responsible for abnormal postures. Hand dystonia prevents daily
      life activities such as writing, which is particularly disabling, since writing is the only
      mean of communication in these patients with significant slurred speech. Treatment is limited
      and only partially effective.

      Low frequency (

Detailed Description

      This study investigates the handwriting performance of an homogeneous cohort of patients with
      Wilson disease and right handed dystonia, after one single inhibitory repetitive transcranial
      magnetic stimulation (rTMS). Fifteen patients with focal right hand dystonia will receive
      randomly either active or sham rTMS (1 Hz) to the left somatosensory cortex (SSC) in one
      single 20 minutes session. Handwriting performance will be measured immediately after this
      unique session (Visual analogic scale of subjective discomfort in writing, DPRE and WCRS
      scales, pen pressure and pen velocity measured on touchpad), compared to scores obtained 24
      hours before the session. Three days later, the patient will receive the other session (sham
      rTMS or active rTMS) and the same parameters will be evaluated.

      This is a single-center, randomized, crossover, prospective, clinical and double-blind study
      (the rTMS session is performed by the neurophysiologist, but the patient and the neurologist
      who will perform the handwriting evaluation are blind to the session).

Study Type

Interventional

Primary Outcome

immediate and significant improvement in writing

Secondary Outcome

 significant improvement in writing

Condition

Wilson Disease

Intervention

Repetitive Transcranial Magnetic Stimulation (rTMS)

Study Arms / Comparison Groups

 Active rTMS
Description:  Repetitive Transcranial Magnetic stimulation: 1 Hz rTMS, delivered to left somatosensory cortex during rest. Intervention is delivered during 20 minutes in one single session.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Device

Estimated Enrollment

15

Start Date

January 2014

Completion Date

February 2016

Primary Completion Date

February 2016

Eligibility Criteria

        Inclusion Criteria:

          -  Wilson disease with focal right hand dystonia

          -  No modification of medical treatment for 6 months

          -  No botulinum toxin administration within the past four months

          -  Right handed

          -  Focal right hand dystonia

          -  Cerebral Magnetic Resonance performed the last 6 months with no other lesion than met
             in Wilson disease

          -  Over 18

          -  Insurance policy holder

          -  Informed consent

        Exclusion Criteria:

          -  Pregnant woman

          -  Guardianship procedure

          -  Seizure history

          -  Other cerebral lesions on cerebral MRI than met in Wilson Disease

          -  Unable to stay quiet for 30 minutes

          -  Handwriting impossible

          -  Contra-indications to repetitive Transcranial Magnetic Stimulation

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Nathalie KUBIS, MD, PhD, 33 1 49 95 83 14/80 88, [email protected]

Location Countries

France

Location Countries

France

Administrative Informations

NCT ID

NCT01980433

Organization ID

P121105

Responsible Party

Sponsor

Study Sponsor

Assistance Publique - Hôpitaux de Paris

Study Sponsor

Nathalie KUBIS, MD, PhD, Study Director, Physiology Department, Lariboisière Hospital

Verification Date

May 2015